Tamika Harris
Psychiatric/Mental Health · Birmingham, ALNPI 1356886949
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 299 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations.
Across 299 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$678
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$566
- Alkermes, Inc.$541
- Vanda Pharmaceuticals Inc.$454
- Johnson & Johnson$407
- plus $2K from 14 others
What the payments were for
- Food & beverage$5,64798%
- Education$1112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $1,034 |
| Otsuka America Pharmaceutical, Inc. | 34 | $678 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $566 |
| Alkermes, Inc. | 22 | $541 |
| Vanda Pharmaceuticals Inc. | 21 | $454 |
| Johnson & Johnson | 17 | $407 |
| Lundbeck LLC | 17 | $352 |
| Teva Pharmaceuticals USA, Inc. | 16 | $349 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $345 |
| Neurocrine Biosciences, Inc. | 10 | $249 |
| Axsome Therapeutics, Inc. | 8 | $230 |
| Corium, LLC | 8 | $142 |
| E.r. Squibb & Sons, L.L.C. | 6 | $109 |
| Almatica Pharma LLC | 4 | $76 |
| Bausch Health US, LLC | 4 | $75 |
| Tris Pharma Inc | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Noven Therapeutics, LLC | 2 | $33 |
| Neos Therapeutics, LP | 1 | $22 |
| Alfasigma USA, Inc. | 1 | $14 |
How this compares
$5,758 in reported general payments places this provider in the 85th percentile of 378 psychiatric/mental health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 27 | $74,478 |
| RexultiBrexpiprazole | 28 | $56,640 |
| TrintellixVortioxetine Hydrobromide | 24 | $20,902 |
| BelsomraSuvorexant | 27 | $12,074 |
| Paliperidone ErPaliperidone | 16 | $4,231 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 47 | $2,106 |
| Quetiapine Fumarate | 76 | $1,920 |
| Duloxetine Hcl | 69 | $1,552 |
| Doxepin Hcl | 47 | $1,444 |
| Mirtazapine | 56 | $1,236 |
| Buspirone Hcl | 63 | $1,178 |
| Lamotrigine | 57 | $963 |
| Divalproex Sodium ErDivalproex Sodium | 19 | $914 |
| Bupropion XlBupropion Hcl | 36 | $901 |
| Oxcarbazepine | 12 | $895 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $407 | $74,47827 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $678 | $56,64028 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $345 | $20,90224 claims |
| Almatica Pharma LLCSertraline Hcl | $76 | $17429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Birmingham
- Yuliya SpencerBirmingham$65K
- David CoffmanBirmingham$13K
- Tiffany WallerBirmingham$12K
- Kellie VaughnBirmingham$12K
- Amanda BoydBirmingham$10K
- Hannah KeslerBirmingham$9K
- Judy ClarkBirmingham$9K
- Jessica AdwellBirmingham$9K
- Pamela Kite TrullBirmingham$9K
- Lacey PodyBirmingham$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.